Inozyme Debt To Equity from 2010 to 2025
| INZY Stock | USD 0.96 0.05 4.75% |
Debt To Equity | First Reported 2010-12-31 | Previous Quarter 0.26657559 | Current Value 0.28 | Quarterly Volatility 0.11394247 |
Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 1.6 M, Interest Income of 8 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.16. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.
Inozyme | Debt To Equity |
Latest Inozyme Pharma's Debt To Equity Growth Pattern
Below is the plot of the Debt To Equity of Inozyme Pharma over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Inozyme Pharma's Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inozyme Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.02 % | 10 Years Trend |
|
Debt To Equity |
| Timeline |
Inozyme Debt To Equity Regression Statistics
| Arithmetic Mean | 0.07 | |
| Geometric Mean | 0.02 | |
| Coefficient Of Variation | 172.67 | |
| Mean Deviation | 0.09 | |
| Median | 0.01 | |
| Standard Deviation | 0.11 | |
| Sample Variance | 0.01 | |
| Range | 0.3235 | |
| R-Value | 0.71 | |
| Mean Square Error | 0.01 | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 0.02 | |
| Total Sum of Squares | 0.19 |
Inozyme Debt To Equity History
About Inozyme Pharma Financial Statements
Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.27 | 0.28 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.